Key Record Dates
| ClinicalTrials.gov Identifier: | NCT02606305 |
|---|---|
| Brief Title: | Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer |
| First Submitted : | November 6, 2015 |
| First Submitted that Met QC Criteria : | November 13, 2015 |
| First Posted : | November 17, 2015 (Estimate) |
| Results First Submitted : | June 12, 2023 |
| Results First Submitted that Met QC Criteria : | January 19, 2024 |
| Results First Posted : | February 14, 2024 |
| Certification/Extension First Submitted : | December 13, 2021 |
| Certification/Extension First Submitted that Met QC Criteria : | December 13, 2021 |
| Certification/Extension First Posted : | December 17, 2021 |
| Last Update Submitted that Met QC Criteria : | January 19, 2024 |
| Last Update Posted : | February 14, 2024 |